Stimulant Treatment During Pregnancy: Care Priorities

Stimulant treatment during pregnancy should connect substance-use treatment with prenatal care, address each woman’s health and daily needs, and plan for support after birth. Treatment does not need to wait until every service is in place. A coordinated plan can address current concerns while helping you reach the other care you need.

The central issue is how care fits together. Pregnancy adds medical considerations, while food access, transportation, parenting duties, and mental health can affect participation in treatment. The ASAM/AAAP clinical guideline recommends prenatal referrals, coordinated treatment, and attention to pregnancy-related needs. It also calls for individualized medication decisions and consideration of added support around birth. These recommendations do not mean every woman needs the same setting or services. They provide a basis for care that responds to your circumstances without treating pregnancy, stimulant use, and life after delivery as separate problems. Source: ASAM/AAAP guideline, pregnancy and postpartum recommendations 33–40.

Why should prenatal and stimulant-use care be coordinated?

Prenatal and stimulant-use care should work together so that pregnancy concerns and treatment decisions inform one another. Understanding substance-use care and the role of contingency management for stimulant use disorder can help clarify how ongoing treatment belongs alongside prenatal visits.

The guideline recommends connecting a pregnant patient with a prenatal provider if she does not already have one. It also states that stimulant-use treatment should not be delayed or withheld because prenatal care has not yet been established. You should not have to complete one part of care before another can begin. Source: ASAM/AAAP guideline, pregnant and postpartum patients assessment section.

Coordination means that clinicians consider how their decisions fit the larger plan. A maternity clinician addresses pregnancy health. A substance-use clinician addresses stimulant-use patterns and treatment. Other professionals may be needed for medical complications or mental health concerns. High-risk pregnancies may warrant maternal-fetal medicine care, when accessible. The guideline supports a multidisciplinary approach, meaning care involving professionals from more than one field. Source: ASAM/AAAP guideline, pregnancy assessment and recommendation 34.

The following table translates those priorities into distinct care responsibilities. It is not a fixed schedule or a promise that one program provides every service.

These responsibilities reflect the guideline’s recommendations for comprehensive assessment, coordinated prenatal treatment, and pregnancy-related support. Source: ASAM/AAAP guideline, recommendations 21–22 and 33–40.

What medical and daily-life needs belong in assessment?

Assessment should consider pregnancy health, stimulant use, mental health, safety, and the conditions affecting daily life. Substance-use assessment helps identify treatment needs, while care coordination and case management concern how different supports fit together.

The guideline calls for attention to factors affecting pregnancy and fetal development. It supports screening for infections transmitted through blood or sexual contact, depression, and nutritional deficiencies. The purpose is to identify needs that require treatment or referral, not to assume that every pregnant woman who uses stimulants has the same complications. Source: ASAM/AAAP guideline, pregnant and postpartum patients assessment section.

A useful assessment also makes room for practical concerns that can otherwise be mistaken for a lack of commitment:

• Food access and nutrition: Reliable access to food and any nutrition concerns deserve attention in the plan.
• Parenting and childcare: Existing caregiving duties can affect the ability to attend prenatal visits and treatment.
• Transportation: A clinically appropriate referral may remain out of reach without a workable way to get there.
• Housing and safety: Unstable housing or unsafe relationships can change which supports are needed.
• Other mental health concerns: Depression, anxiety, ADHD, trauma-related concerns, and other substance use may need care alongside stimulant-use treatment.

The guideline recommends reviewing eligibility for available pregnancy and parenting resources, including childcare assistance and WIC, a nutrition program. Eligibility and local availability require confirmation; a referral is not a guarantee of assistance. It also recommends treating co-occurring psychiatric conditions alongside stimulant use disorder. Source: ASAM/AAAP guideline, recommendations 21–22, 33, and 44.

Drug testing deserves a clear explanation, too. For pregnant patients, the guideline advises clinicians to weigh potential benefits and harms and obtain informed consent unless an immediate clinical need makes consent impossible. Testing should not replace a broader clinical assessment. These are clinical recommendations, not assurances about reporting requirements or legal outcomes. Source: ASAM/AAAP guideline, recommendation 36.

How can behavioral treatment fit alongside prenatal care?

Behavioral treatment can address stimulant-use goals while prenatal care continues. Contingency management is a specific treatment approach; group-based substance-use care describes a treatment format. Those terms explain different parts of a plan and should not be treated as interchangeable.

Contingency management uses tangible incentives linked to specific treatment goals. The ASAM/AAAP guideline identifies it as the current standard of care for stimulant use disorder and recommends it as a primary treatment component alongside other psychosocial treatments. Psychosocial treatment addresses behavior, thoughts, relationships, and social circumstances. Source: ASAM/AAAP guideline, key takeaways and recommendations 5–6.

During pregnancy, the guideline says clinicians can consider incentives for prenatal appointment attendance when feasible, in addition to usual treatment targets. Evidence about improving prenatal attendance is mixed and limited in quality. This supports considering the approach, not promising that incentives will produce a particular pregnancy or treatment outcome. Source: ASAM/AAAP guideline, recommendation 39 and supporting discussion.

Other behavioral care may help a woman recognize situations linked to use and practice different responses. Cognitive behavioral therapy, or CBT, focuses on connections among thoughts, feelings, and behavior. For stimulant use disorder, the guideline supports CBT alongside contingency management. Pregnancy-related treatment may also include parenting-focused and family-based approaches when appropriate. Source: ASAM/AAAP guideline, recommendations 6 and 38.

In practice, that means treatment can address the actual circumstances surrounding use. Pressure to stay awake, relationship strain, or distress may require different responses. A plan that considers those circumstances can be more specific than a general instruction to avoid substances. NIDA describes effective treatment as tailored to a person’s substance-use patterns and medical, mental health, and social needs. Behavioral care supports that work; it does not replace prenatal care or treatment for an acute medical concern. Source: NIDA, Treatment and Recovery.

Why do medication and breastfeeding decisions need individual advice?

Medication and breastfeeding decisions require individual clinical advice because the reason for treatment, the substance involved, pregnancy, and infant health all matter. The guideline calls for weighing risks and benefits to the fetus or infant when medications are used for stimulant use disorder, intoxication, or withdrawal. Source: ASAM/AAAP guideline, recommendation 37.

A prescription stimulant used for ADHD is not the same clinical situation as nonprescribed stimulant use. The guideline recognizes that ADHD and stimulant use disorder can occur together and recommends addressing both. Pregnancy adds considerations that need a prescriber’s review. A general discussion of stimulant risks cannot determine whether a particular woman should start, continue, change, or stop a prescribed medicine. Source: ASAM/AAAP guideline, recommendations 26 and 37.

The guideline also discusses off-label medicines for stimulant use disorder. Off-label means a medicine is being considered for a use outside its approved indication. That discussion is not evidence that a particular medicine is appropriate during pregnancy, and it does not establish that Women’s Recovery provides it. Medication decisions remain separate from this general education.

Breastfeeding needs equally careful advice. The guideline recommends against breastfeeding during active stimulant use, except when the stimulant is taken as prescribed. The prescription exception does not establish that every medicine is suitable for every breastfeeding parent and infant. Maternity, prescribing, and infant-care clinicians should guide the individual decision. If nonprescribed stimulant use is active, seek prompt clinical guidance about feeding rather than assuming breastfeeding is safe. Source: ASAM/AAAP guideline, recommendation 41.

These decisions should be addressed before birth when possible and reviewed if circumstances change. This article provides no medication doses, stopping schedule, or interval after substance use when breastfeeding becomes safe. Those details cannot be established from a general description of stimulant treatment.

Why can support needs increase around birth and postpartum?

Support may need to increase around birth rather than end when pregnancy does. Connecting postpartum outpatient care with continuing-care planning means considering the next phase before an existing treatment arrangement ends.

The guideline advises clinicians to consider additional treatment support around birth because postpartum stress may increase the risk of a return to stimulant use. This is a conditional recommendation based on very limited evidence. It supports paying attention to this period without assuming every woman will experience a return to use. Source: ASAM/AAAP guideline, recommendation 40.

Useful support can take several forms, depending on assessment and available resources:

• Continued behavioral treatment: Keep stimulant-use care connected as pregnancy ends and parenting demands change.
• Mental health attention: Assess new or worsening depression, anxiety, or other psychiatric concerns alongside substance use.
• Medical coordination: Keep postpartum, prescribing, and infant-care decisions connected where relevant.
• Practical assistance: Revisit food access, childcare, transport, and housing needs rather than assuming earlier arrangements still fit.

These priorities follow the guideline’s recommendations for concurrent treatment, pregnancy-related resources, and added support around birth. They are care-planning considerations, not a list of services guaranteed by one organization. Source: ASAM/AAAP guideline, recommendations 21–22, 33, and 40.

If stimulant use returns, the response should include reassessing treatment and current safety needs rather than treating the event as proof that care has failed. NIDA explains that a return to use can signal a need to resume, modify, or change treatment. It can also be dangerous, so the immediate response depends on the person’s symptoms and situation. Source: NIDA, Treatment and Recovery.

Women’s Recovery provides outpatient mental health, trauma, and substance-use programs in Denver, CO, including PHP and Intensive Outpatient Program (IOP). It does not provide onsite detox, residential, or inpatient care. Its general program information does not confirm a specialized pregnancy program. Explore current programs or contact Women’s Recovery at 833.754.0554 to discuss outpatient options. Prenatal care remains a separate, essential part of coordinated treatment.

Frequently asked questions

Does needing treatment mean prenatal care should wait?

No. Prenatal care and stimulant-use treatment should proceed together. The ASAM/AAAP guideline recommends a prenatal referral when care is not established, while stating that stimulant-use treatment should not be delayed or withheld in the absence of prenatal care. One service should not become a prerequisite that prevents access to the other.

Can parenting and food-access needs belong in the care plan?

Yes. The guideline recommends attention to pregnancy and parenting needs, including eligibility for resources such as childcare assistance and WIC. Food access, housing, and transportation can also affect treatment access. Including these concerns helps connect the clinical plan to daily life, although eligibility and the availability of assistance must be confirmed.

Does this article confirm a specialized pregnancy program?

No. General recommendations for stimulant treatment during pregnancy do not establish that Women’s Recovery offers a specialized pregnancy program. Women’s Recovery provides outpatient mental health, trauma, and substance-use programs in Denver, including PHP and IOP. Individual assessment and coordination with prenatal clinicians are needed to determine an appropriate care arrangement.

Should severe symptoms be routed to routine admissions?

No. Chest pain, seizures, severe confusion, dangerous overheating, trouble breathing, or suspected overdose require immediate emergency help through 911. A routine admissions call cannot replace emergency medical assessment. For a mental-health crisis or suicidal thoughts, call or text 988; if there is immediate danger, call 911 instead.